Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study

Clinical Benefit of Pembrolizumab in Advanced Urothelial Cancer Patients in Real-Life Setting: An Efficacy and Safety Monocentric Study

Background: Pembrolizumab is approved for patients with metastatic urothelial carcinoma (UC) who progressed under platinum therapy. The aim of this study was to assess the efficacy and safety of pembrolizumab in a cohort of real-life UC patients. Methods: This retrospective, observational study incl...

Full description

Bibliographic Details
Main Authors: Elodie Dang, Alexandre Vallée, Coralie Lepage-Seydoux, Karine Sejean, Brigitte Bonan, Christine Abraham, Philippe Beuzeboc, Raffaele Ratta
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Current Oncology
Subjects:
immune checkpoint inhibitors
immunotherapy
pembrolizumab
programmed cell death 1 receptor
urinary bladder neoplasms
Online Access:https://www.mdpi.com/1718-7729/29/2/80

Internet

https://www.mdpi.com/1718-7729/29/2/80

Similar Items